Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

@article{Kantarjian2007UpdateOT,
  title={Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.},
  author={Hagop M Kantarjian and Susan M O'Brien and Jianqin Shan and Ahmed Aribi and Guillermo Garcia-Manero and Elias J Jabbour and Farhad Ravandi and Jorge E. Cortes and Jan Davisson and Jean-Pierre Issa},
  journal={Cancer},
  year={2007},
  volume={109 2},
  pages={265-73}
}
BACKGROUND Therapy for patients with myelodysplastic syndrome (MDS) with hypomethylating agents, like decitabine and 5-azacitidine, has produced favorable results. In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy. METHODS One hundred fifteen patients with higher risk MDS who received treatment with decitabine were reviewed. Patients received decitabine… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
46 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…